# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.
Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages ...
The gross proceeds to Arcutis from the offering are expected to be approximately $150.0 million, before deducting underwriting ...
Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone pay...
Goldman Sachs analyst Jonathan Block maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral and raises the price tar...